GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (OTCPK:IDRSF) » Definitions » Buyback Yield %

IDRSF (Idorsia) Buyback Yield % : 0.03 (As of Dec. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Idorsia's current buyback yield was 0.03%.


Idorsia Buyback Yield % Historical Data

The historical data trend for Idorsia's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Buyback Yield % Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial -0.03 -20.03 -0.28 -0.01 0.05

Idorsia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.08 -

Competitive Comparison of Idorsia's Buyback Yield %

For the Biotechnology subindustry, Idorsia's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Idorsia's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Idorsia's Buyback Yield % falls into.



Idorsia Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Idorsia's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.228 + 0) / 438.12615
=0.05%

Idorsia's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 487.71513
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.


Idorsia Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Idorsia's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Idorsia Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

From GuruFocus

Q3 2023 Idorsia Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Full Year 2020 Idorsia Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Half Year 2021 Idorsia Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Half Year 2022 Idorsia Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2023 Idorsia Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Idorsia Ltd - Special Call Transcript

By GuruFocus Research 02-13-2024